|
|
Volumn 29, Issue 6 Suppl 16, 2002, Pages 3-9
|
|
Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
BEVACIZUMAB;
ENDOTHELIAL CELL GROWTH FACTOR;
LYMPHOKINE;
MONOCLONAL ANTIBODY;
SIGNAL PEPTIDE;
VASCULOTROPIN;
VASCULOTROPIN A;
ANIMAL;
CELL HYPOXIA;
CLINICAL TRIAL;
DRUG ANTAGONISM;
DRUG SCREENING;
HUMAN;
MULTIMODALITY CANCER THERAPY;
NEOPLASM;
NEOVASCULARIZATION (PATHOLOGY);
PATHOLOGY;
REVIEW;
VASCULARIZATION;
ANGIOGENESIS INHIBITORS;
ANIMALS;
ANTIBODIES, MONOCLONAL;
CELL HYPOXIA;
CLINICAL TRIALS;
COMBINED MODALITY THERAPY;
DRUG SCREENING ASSAYS, ANTITUMOR;
ENDOTHELIAL GROWTH FACTORS;
HUMANS;
INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS;
LYMPHOKINES;
NEOPLASMS;
NEOVASCULARIZATION, PATHOLOGIC;
VASCULAR ENDOTHELIAL GROWTH FACTOR A;
VASCULAR ENDOTHELIAL GROWTH FACTORS;
MLCS;
MLOWN;
|
|
EID: 0036984738
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: 10.1053/sonc.2002.37265 Document Type: Review |
|
Times cited : (293)
|
|
References (30)
|
